D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea · Delayed Price · Currency is KRW

60,900

-4,800 (-7.31%)

Aug 11, 2026, 3:30 PM KST

79.25% (1Y)

Market Cap	2.79T +89.8%
Revenue (ttm)	3.01B -71.9%
Net Income	-23.20B
EPS	-774.30
Shares Out	45.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,942,853
Open	64,700
Previous Close	65,700
Day's Range	59,100 - 66,500
52-Week Range	32,100 - 116,600
Beta	1.64
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About D&D Pharmatech

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 347850

Full Company Profile

Financial Performance

In 2025, D&D Pharmatech's revenue was 4.30 billion, a decrease of -62.42% compared to the previous year's 11.44 billion. Losses were -23.55 billion, -17.71% less than in 2024.

Financial Statements